Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus.
Steven RellaJoseph OnyiahChelsea BakerVatsala SinghAndrew HerNeda RasouliPublished in: Therapeutic advances in endocrinology and metabolism (2023)
SIB is the first study to examine the effects of GLP-1 receptor agonists on intestinal permeability in humans and will provide important data on their impact on systemic inflammation and intestinal permeability in the setting of T2D and obesity.